Abstract A study was carried out on the effect of a large number of B12 analogues on the coenzyme B12-dependent enzyme ethanolamine deaminase. The analogues tested included MeB12, EtB12, AB12, RB12, BB12, IB12, DB12, UB12, CNB12, and OHB12. DB12 was found to be capable of replacing the coenzyme. In contrast, all the rest of the analogues were inhibitors. With all the inhibitors except IB12, the inhibition was progressive, with the reaction velocity decaying exponentially with time to a final, constant value. The extent of inhibition by IB12 was independent of time; kinetics showed that this inhibition was competitive with respect to the coenzyme. Inhibition by MeB12 was also found to be competitive with DMBC, when its effect of the initial reaction rate was considered. Studies of the time-dependent increase in the extent of inhibition observed with MeB12 showed that the rate constant for this process (the deactivation constant) followed saturation kinetics with respect to the concentration of inhibitor. A similar dependence of the deactivation constant on the inhibitor concentration was observed with RB12. The time-dependent decrease in the reaction rate caused by this derivative was found to be irreversible. Kinetic studies performed at the end of the decay period showed that RB12 behaved as a competitive inhibitor with respect to the coenzyme, but that its Ki at the end of this period was much lower than the Ki estimated for the beginning of the reaction. Furthermore, the Vm for ethanolamine deaminase at the end of the decay period was only one-sixth of the Vm of the uninhibited enzyme. Light scattering studies and studies of the effect of enzyme concentration on the characteristics of the decay indicated that the inhibition is not associated with polymerization or depolymerization of the enzyme. Experiments with tritiated MeB12 showed that the progressive inhibition induced by this derivative is not accompanied by cleavage of the carbon-cobalt bond. Titration experiments with RB12 have shown that the progressive inhibition is fully expressed at an inhibitor to enzyme ratio of 2:1. These results can be explained by a model in which the presence of inhibitor induces a change in the enzyme from the form isolated in the purification to a form with a lower Vm and a much greater affinity for the inhibitor. The abbreviations used are: MeB12, methylcobalamin; EtB12, β-hydroxyethylcobalamin; AB12, β-(2-tetrahydropyryloxy)ethylcobalamin; RB12, 1-O-methyl-5-deoxyribosylcobalamin; BB12, δ-(9-adenyl)butylcobalamin; IB12, 5'-deoxyinosylcobalamin; DB12, 2',5'-dideoxyadenosylcobalamin; UB12, 5'-deoxyuridylcobalamin; CNB12, cyanocobalamin; OHB12, hydroxocobalamin; DMBC, 5'-deoxyadenosylcobalamin.
Read full abstract